Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620346 | 0.96 | PTGDR2 (0.46) | PTGDR2POLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24315790 | 0.87 | PTGDR2 (0.43) | PTGDR2POLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24317831 | 0.83 | PTGDR2 (0.43) | PTGDR2POLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL24315834 | 0.81 | POLB (0.57) | POLBALDH1A1SMN1; SMN2TSHRCYP2C9 | |
| SCHEMBL26620030 | 0.80 | PTGDR2 (0.48) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL26620040 | 0.78 | PTGDR2 (0.47) | PTGDR2TSHRCYP3A4NPC1CNR1 | |
| SCHEMBL24316060 | 0.78 | PTGDR2 (0.48) | PTGDR2POLBALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26620334 | 0.78 | PTGDR2 (0.48) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL26620028 | 0.78 | PTGDR2 (0.46) | PTGDR2ALDH1A1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL26620050 | 0.77 | L3MBTL1 (0.51) | POLBALDH1A1SMN1; SMN2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | PTGDR2 3825/4885POLB 3232/4885ALDH1A1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.